The New York TimesAstraZeneca to Buy Alexion for $39 Billion to Add Rare-Disease TreatmentsDec 12, 2020Michael de la MercedBy Michael de la Mercedmore_vert
Financial TimesAstraZeneca to buy Alexion in $39bn immunology dealDec 12, 2020Sarah Neville, Donato Paolo Mancini & Arash MassoudiBy Sarah Neville, Donato Paolo Mancini & Arash Massoudimore_vert
BloombergBig Pharma Deals: AstraZeneca Buying Alexion Pharmaceuticals for $39 BillionDec 12, 2020John Lauerman, Tim Loh & Stephanie BakerBy John Lauerman, Tim Loh & Stephanie Bakermore_vert
FiercePharmaAstraZeneca snaps up Alexion for $39B in a leap toward CEO's $40B revenue goalDec 12, 2020Angus LiuBy Angus Liumore_vert
ReutersAstraZeneca to buy Alexion for $39 billion to expand in immunologyDec 12, 2020Ludwig BurgerBy Ludwig Burgermore_vert
Business WireAstraZeneca to Acquire Alexion, Accelerating the Company's Strategic and Financial DevelopmentDec 12, 2020more_vert